Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun 15;199(12):1851-61.
doi: 10.1086/599123.

Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women

Diljeet K Singh  1 , Kathryn Anastos, Donald R Hoover, Robert D Burk, Qiuhu Shi, Louis Ngendahayo, Eugene Mutimura, Antonio Cajigas, Venerand Bigirimani, Xiaotao Cai, Janvier Rwamwejo, Magalis Vuolo, Mardge Cohen, Philip E Castle
Affiliations

Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women

Diljeet K Singh et al. J Infect Dis. .

Abstract

Background: Data on human papillomavirus (HPV) prevalence are essential for developing cost-effective cervical cancer prevention programs.

Methods: In 2005, 710 human immunodeficiency virus (HIV)-positive and 226 HIV-negative Rwandan women enrolled in an observational prospective cohort study. Sociodemographic data, CD4+ cell counts, and cervical specimens were obtained. Cervicovaginal lavage specimens were collected from each woman and tested for >40 HPV types by a polymerase chain reaction assay; HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were considered primary carcinogenic HPV types.

Results: The prevalence of HPV was higher in HIV-positive women than in HIV-negative women in all age groups. Among HIV-infected women, 69% were positive for >or=1 HPV type, 46% for a carcinogenic HPV type, and 10% for HPV-16. HPV prevalence peaked at 75% in the HIV-positive women aged 25-34 years and then declined with age to 37.5% in those >or=55 years old (Ptrend<.001). A significant trend of higher prevalence of HPV and carcinogenic HPV with lower CD4+ cell counts and increasing cytologic severity was seen among HIV-positive women.

Conclusions: We found a higher prevalence of HPV infection in HIV-positive than in HIV-negative Rwandan women, and the prevalence of HPV and carcinogenic HPV infection decreased with age.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: none reported.

Figures

Figure 1
Figure 1
Prevalence of infection with any human papillomavirus (HPV) type (A) and any carcinogenic HPV type (B), by age group and human immunodeficiency virus (HIV) infection status. A, Prevalence of HPV infection differed significantly according to age among HIV-negative (P = .003) and HIV-positive women (P < .001). B, Prevalence of noncarcinogenic HPV infection differed significantly according to age among HIV-negative (P = .016) and HIV-positive women (P < .001). Whisker bars, binomial 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9. - PubMed
    1. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55. - PubMed
    1. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70. - PubMed
    1. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Can Med Assoc J. 2007;177:469–79. - PMC - PubMed
    1. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multi-centre phase II efficacy trial. Lancet Oncol. 2005;6:271–8. - PubMed

Publication types